|Denumire||Organon & Co.|
|Capitalizare bursieră||6,270 mld. USD|
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon has a strong focus on women's health, with a specialisation in the a few, core therapeutic fields induding reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anaesthesia. Organon & Co therapies are available around the world, serving patients in more than 140 markets. The firm was founded in 2020.
The company has an emphasis on the development of biosimilar medicines, which are therapies that aim to offer patients more treatment options while also reducing the high healthcare costs associated with more complex biologic therapies. Company products include Nexplanon/lmplanon, a long-acting reversible contraceptive, immunology products such as Brenzys, Renflexis, and Hadlima, and oncology products such as Ontruzant and Aybintio.
The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organisations, pharmacy benefit managers, and other institutions. The company also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and pain management medications.